Activated protein C resistance phenotype in patients with antiphospholipid antibodies

Journal of Laboratory and Clinical Medicine

Volumn 130, Issue 2, 1997, Pages 202-208

  Aznar, Justo ^a,b   Villa, Piedad ^a   España, Francisco ^a   Estellés, Amparo ^a   Grancha, Salvador ^a   Falcó, Cristina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Departamento de Biopatologia Clinica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031214368     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(97)90097-4     Document Type: Article

References (44)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-9.
3. Zoller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
4. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
5. Dahlbäck B. Inherited thrombophilia: resistance to activated protein CI as pathogenic factor of venous thromboembolism. Blood 1995;85:607-14.
6. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-93.
7. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-22.
8. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evant B. Activated protein C resistance caused by Arg 506 Gln mutation in factor Va. Lancet 1994;343:1362-3.
9. Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JT, et al. Association of idiopathic thromboembolism with single point mutation at Arg 506 of factor V. Lancet 1994;343:1535-6.
10. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994;5:37-41.
11. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemost 1995;74:797-8.
12. Hampton KK, Path MRC, Preston FE, Greaves M. Resistance to activated protein C. N Engl J Med 1994;331:130.
13. Tsakiris DA, Yasikoff ML, Wolf F, Marbet GA. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Ann Hematol 1995;71:195-8.
14. Halbmayer WM, Haushofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 1994;72:645-6.
15. Griffin JH, Heeb MJ, Kojima Y, Fernández JA, Kojima K, Hackeng TH, et al. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995;74:444-8.
16. Ruiz-Argüelles GJ, Garcés-Eisele D, Alarcón-Segovia D, Ruiz-Argüelles A. Activated protein resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;7:344-8.
17. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig CH, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56-65.
18. Bokarewa MI, Blomback M, Bremme K. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Blood Coagul Fibrinolysis 1995;6:417-22.
19. Nakamura N, Azuma CH, Akamizu T, Sugawa H, Matsuda F, Mitsuda N, et al. Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochem Biophys Res Commun 1994;203: 1789-94.
20. Harris EN, Gharavi AE, Loizon S. Crossreactivity of antiphospholipids antibodies. J Clin Lab Immunol 1985;16:1-6.
21. Gharavi AE, Harris EN, Asherson RA, Hughes GV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
22. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Ann Rev Cell Biol 1993;9:1-26.
23. Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J 1986;238:151-7.
24. Walker FJ. Regulation of activated protein C by protein S: the role of phospholipid in factor Va inactivation. J Biol Chem 1981;256:11128-31.
25. Smirnov MD, Esmon CT. Phosphatidyl ethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994;269:816-9.
26. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869-80.
27. Esmon CT, Schwarz HP. An update on clinical basis aspects of the protein C anticoagulant pathway. Trend Cardiovasc Med 1995;5:141-8.
28. 2-glycoprotein I. Br J Haematol 1995;90:204-6.
29. Manorhan A, Gottlieb P. Bleeding in patients with lupus anticoagulant. Lancet 1984;2:171.
30. Ordi J, Vilardel M, Oristrell J, Valdés M, Kuobel A, Alijotas J, et al. Bleeding in patients with lupus anticoagulant. Lancet 1984;2:868-9.
31. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-3.
32. Villa P, Aznar J, Jorquera JI, Casaña P. Laboratory diagnosis of APC-resistance in patients with lupus anticoagulant. Thromb Haemost 1995;74:1606-7.
33. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagul Fibrinolysis 1995;6:245-7.
34. España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays: enzyme levels are proportional to total protein C level. Thromb Haemost 1996;75:56-61.
35. Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M. Foncuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992;68:268-72.
36. Ousting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
37. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-7.
38. Marciniak E, Romond ED. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-32.
39. Jorquera JI, Aznar J, Fernández MA, Montoro JM, Curats R, Casana P. A modification of the APC resistance test and its application to the study of patients on coumarin therapy. Thromb Res 1996;82:217-24.
40. Dahlbäck B. Are we ready for factor V Leiden screening? Lancet 1996;347:1346-7.
41. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986;314:1193-4.
42. Keeling DM, Wilson AJG, Mackie IJ, Isenberg DA, Machin SJ. Role of β-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993;46:908-11.
43. Oosting JD, Preissner KT, Derksen RHWM, de Groot PC. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993;85:761-8.
44. Freyssinet JM, Cazenave JP. Lupus like anticoagulant modulation of the protein C pathway and thrombosis. Thromb Haemost 1987;58:679-81.